(Q51063040)

28 March 2018

title

The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. (English)

1 reference

28 March 2018

author

Jolanta M Siller-Matula

1

1 reference

28 March 2018

Bernd Jilma

5

object named as

Bernd Jilma

1 reference

28 March 2018

author name string

Carina Gruber

2

1 reference

28 March 2018

Marcel Francesconi

3

1 reference

28 March 2018

Cornelia Dechant

4

1 reference

28 March 2018

Georg Delle-Karth

6

1 reference

28 March 2018

Katharina Grohs

7

1 reference

28 March 2018

Andrea Podczeck-Schweighofer

8

1 reference

28 March 2018

Günter Christ

9

1 reference

28 March 2018

language of work or name

English

0 references

publication date

1 January 2015

1 reference

28 March 2018

published in

Clinical Science

1 reference

28 March 2018

volume

128

1 reference

28 March 2018

issue

2

1 reference

28 March 2018

page(s)

121-130

1 reference

28 March 2018

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

cites work

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Response variability to P2Y12 receptor inhibitors: expectations and reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Ticagrelor: from discovery to Phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Pharmacokinetic basis of the antiplatelet action of prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Cangrelor: an emerging therapeutic option for patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Why have studies of tailored anti-platelet therapy failed so far?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Clinical end points in coronary stent trials: a case for standardized definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

The universal definition of myocardial infarction: a consensus document: ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Platelet function monitoring in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20140310

21 January 2018

Identifiers

DOI

10.1042/CS20140310

1 reference

28 March 2018

PubMed ID

25124236

1 reference

28 March 2018